Headache; Sinus congestion, pressure and drainage; Sinus congestion, pressure and drainage; Sinus congestion, pressure and drainage; Muscle and joint aches; Muscle and joint aches; Fatigue; Chills; Fever/Fever ranged to 102.1; Nausea; Swollen lymph nodes; Weakness; Sore arm; The patient received third/booster dose of BNT162b2; There were periods of perceived difficulty breathing.; These lasted approximately 36 hours with the exception that the headache became an intractable migraine that lasted 4 days.; This is a spontaneous report from a non-contactable consumer, the patient. A 61-year-old non-pregnant female patient received third (booster) dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FF2590) via an unspecified route of administration in the left arm on 05Nov2021 at 10:15 (at the age of 61-years-old) as a single dose for COVID-19 immunisation. The medical history included migraines, non-alcoholic fatty liver, obesity, endometriosis and known allergy to sulfa drugs.  Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient received other vaccine within four weeks prior to the vaccination which included influenza vaccine (MANUFACTURER UNKNOWN) for an unknown indication in the left arm. The concomitant medications included levothyroxine (MANUFACTURER UNKNOWN), acetylsalicylic acid/caffeine/paracetamol (EXCEDRIN MIGRAINE) and diphenhydramine hydrochloride (BENADRYL), all for unknown indications from unknown dates and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6202) via an unspecified route of administration in the left arm on 09Mar2021 (at the age of 60-years-old) and second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the left arm on 30Mar2021 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. The patient previously received hydrocodone bitartrate/paracetamol (VICODIN) and experienced allergy. On 05Nov2021 at 23:00, the patient began with sore arm. On 06Nov2021,approximately 12 hours later, the patient experienced headache, sinus congestion, pressure and drainage, muscle and joint aches, fatigue and chills. Approximately 6 hours after that, the patient developed fever, nausea and swollen lymph nodes and weakness. The fever ranged to 102.1 (units unspecified). On an unknown date in Nov2021, there were periods of perceived difficulty breathing. The events lasted approximately 36 hours with the exception that the headache became an intractable migraine that lasted 4 days. On 06Nov2021, the patient underwent body temperature test and the result was found to be 102.1(unspecified units). The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events difficulty breathing, intractable migraine, sore arm, headache, sinus congestion, pressure and drainage, muscle and joint aches, fatigue, chills, fever/fever ranged to 102.1, nausea, swollen lymph nodes and weakness were resolved on an unknown date in Nov2021.   No follow-up attempts are possible. No further information is expected.